BioLine Rx (FRA:YP2) EBITDA Margin %: -471.19% (As of Mar. 2026)


FRA:YP2 BioLine Rx Ltd FRA:YP2
21 GF Score
Price €2.54
! 5 Warning Signs
View Full Analysis

What is BioLine Rx EBITDA Margin %?

BioLine Rx FRA:YP2 -22.09% 21 EBITDA Margin % is -471.19% as of Mar. 2026. GuruFocus rates FRA:YP2 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review. Among 942 Biotechnology companies, BioLine Rx ranks worse than 73.25% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. BioLine Rx's EBITDA for the three months ended in Mar. 2026 was €-1.95 Mil. BioLine Rx's Revenue for the three months ended in Mar. 2026 was €0.41 Mil. Therefore, BioLine Rx's EBITDA margin for the quarter that ended in Mar. 2026 was -471.19%.

BioLine Rx  (FRA:YP2) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

BioLine Rx EBITDA Margin % Related Terms

BioLine Rx EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for BioLine Rx's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLine Rx EBITDA Margin % Chart

BioLine Rx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -1,189.19 13.54 -21.33

BioLine Rx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,238.98 -1,145.45 -129.67 -988.55 -471.19

FRA:YP2 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, BioLine Rx's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where BioLine Rx's EBITDA Margin % falls into.


FRA:YP2
21GF Score
BioLine Rx Ltd FRA:YP2
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLine Rx EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

BioLine Rx's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-0.215/1.008
=-21.33 %

BioLine Rx's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.946/0.413
=-471.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -471.19% mean?
BioLine Rx (FRA:YP2) has a EBITDA Margin % of -471.19% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioLine Rx and its competitors. According to the industry distribution chart, BioLine Rx ranks #690 out of 942 companies in the Biotechnology industry, placing it in the top 73.2%.
Is BioLine Rx's EBITDA Margin % too high?
BioLine Rx's current EBITDA Margin % is -471.19%. Based on the distribution chart, BioLine Rx ranks #690 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioLine Rx has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLine Rx ranks #690 out of 942 companies for EBITDA Margin %. This places BioLine Rx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioLine Rx and its competitors. BioLine Rx's current EBITDA Margin % is -471.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (FRA:YP2) has a current EBITDA Margin % of -471.19%. The current EBITDA Margin % is -471.19%. BioLine Rx's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BioLine Rx (FRA:YP2), the current EBITDA Margin % is -471.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLine Rx Business Description

Other Exchanges BLRX:USABLRX:Israel
Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
21GF Score

Get the complete analysis for FRA:YP2

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.54
Price